Litigation Details for Novo Nordisk Inc. v. Mylan Institutional LLC (D. Del. 2019)

✉ Email this page to a colleague

Docket	⤷ Sign Up	Date Filed	2019-08-20
Court	District Court, D. Delaware	Date Terminated	2021-04-06
Cause	35:271 Patent Infringement	Assigned To	Kent A. Jordan
Jury Demand	None	Referred To	Sherry R. Fallon
Parties	MYLAN INSTITUTIONAL LLC
Patents	6,268,343; 7,762,994; 8,114,833; 8,579,869; 8,846,618; 9,155,776; 9,265,893; RE41,956
Attorneys	Jason James Rawnsley
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2019-08-20	1	Complaint	United States Patent Nos. 6,268,343 (the “’343 patent”), 7,762,994 (the “’994 patent”), 8,114,833 (the… COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 6,268,343 21. Novo Nordisk re-alleges…(the “’833 patent”), 8,579,869 (the “’869 patent”), 8,846,618 (the “’618 patent”), 9,265,893 (the “’893… 1. This is an action for patent infringement under the patent laws of the United States, Title…’893 patent”), and RE41,956 (the “RE ’956 patent”), which cover inter alia, Victoza® and/or its use.	External link to document
2020-10-08	110	Notice of Service	Supplemental Invalidity Contentions Regarding U.S. Patent Nos. 6,268,343; 8,114,833; 8,846,618; 9,265,893; and RE41,956…2019 6 April 2021 1:19-cv-01551 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-10-08	111	Notice of Service	Initial Invalidity Contentions Regarding U.S. Patent Nos. 6,268,343; 8,114,833; 8,846,618; 9,265,893; and RE41,956…2019 6 April 2021 1:19-cv-01551 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document